Dialysis hypotension

WEDNESDAY, Nov. 6, 2024 -- Clinical data and machine learning can help to predict intradialytic hypotension (IDH) for patients undergoing hemodialysis , according to a study published online Sept. 14 in the Journal of Kidney Care . Shamsul K. Masum, Ph.D., from the University of Portsmouth in the United Kingdom, and colleagues investigated the scope of machine learning techniques in predicting IDH by analyzing various standard clinical variables measured by clinicians. The dataset included 73,323 hemodialysis sessions (3,944 patients) with 36,662 IDH events seen at 10 centers during 2000 to 2020. The researchers found that systolic blood pressure (SBP) and diastolic BP (DBP) were key predictor variables. Predialysis, patients with IDH had lower SBP, as well as a greater percentage drop in SBP during dialysis. Similarly, people with IDH had lower predialysis DBP and a greater percentage drop in their DBP. IDH probability increased with lower pre-SBP, greater delta-systolic, and increased weight loss. Highest specificity (73.9 percent) and highest overall predictive accuracy (75.5 percent) were seen with a machine learning model with Random Forest. However, a model with Bidirectional Long Short-Term Memory (Bi-LSTM) achieved the highest sensitivity (78.5 percent) in predicting IDH. In a separate validation dataset, the Bi-LSTM model achieved accuracy of 74.09 percent, sensitivity of 74.81 percent, specificity of 73.3 percent, and a receiver operating characteristic-area under the curve (ROC-AUC) of 0.816. Based only on predialysis data, the prediction performance dropped to accuracy of 68.60 percent, specificity of 69.81 percent, sensitivity of 67.40 percent, and an ROC-AUC of 0.757. "A prediction model using machine learning algorithms offers great promise as a tool in identifying patients at risk of IDH in advance," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

The Renal Research Institute (RRI), a division of Fresenius Medical Care, and the Company's Digital Technology & Innovation (DTI) team, developed a secure data pipeline that collects real time data from dialysis machines and medical sensors. Download Image (PNG 2531KB) Contact Leif Heussen Senior Manager External Communications T: +49 (0) 6172 608-4030 leif.heussen@fresenius.com Documents Text as PDF document (PDF, 86 KB) Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, has won the prestigious CIO 100 Award. The Company was recognized for its groundbreaking efforts to develop a tool to predict intradialytic hypotension (IDH) before it occurs in hemodialysis patients. IDH is a frequent complication of long-term hemodialysis that can lead to serious clinical outcomes including death and is difficult to predict. The Renal Research Institute (RRI), a division of Fresenius Medical Care, and the Company's Digital Technology & Innovation (DTI) team, developed a secure data pipeline that collects real time data from dialysis machines and medical sensors throughout the United States at a high frequency. The increased data flow allows machine learning and cloud computing to develop a real-time IDH prediction for patients. Clinic teams use the information to specially tailor treatment plans and proactively intervene at the point of care preventing IDH, potentially improving patients’ morbidity and mortality. “This is a true example of partnership, collaboration, and teamwork, and we are proud that our commitment to bring it to the next level of these exciting technologies will result in a better care experience for our patients, and most importantly, improve quality of life and patient outcomes,” said Franklin W. Maddux, MD, Global Chief Medical Officer and Member of the Board of Fresenius Medical Care. The CIO 100 Awards celebrates 100 organizations and the teams within them that are using IT in innovative ways to deliver business value, whether by creating competitive advantage, optimizing business processes, enabling growth, or improving relationships with customers. Because it is given to companies and not individuals, it is an acknowledged mark of enterprise excellence. The Renal Research Institute (RRI) is dedicated to measurably improving outcomes in patients suffering from chronic kidney disease (CKD) through research, technical innovation, implementation of processes and education. RRI strives to achieve its goals through collaboration with national and international academic partners, industry, and not-for-profit organizations operating in the field of kidney disease. RRI fosters its relationship with academic centers of the highest caliber through partnerships. RRI promotes research and education programs with an emphasis on international clinical fellows, scientists, and renal nurses. Through partnerships, RRI is able to enhance the spectrum of comprehensive renal services by advancing peritoneal and hemodialysis therapies through clinical research and the application of practice guidelines and new technology. For more information, visit the Renal Research Institute’s website at www.renalresearch.com .